Alteogen receives positive CHMP opinion for aflibercept biosimilar, 'Eyluxvi (ALT-L9)'

28 July 2025 - Upon approval, Eyluxvi will be Alteogen's second biosimilar product, following a Herceptin biosimilar by Alteogen's license ...

Read more →

CHMP recommends EU approval of Henlius’ denosumab biosimilar HLX14

28 July 2025 - Shanghai Henlius Biotech announced today that the EMA's CHMP has adopted a positive opinion for HLX14, the ...

Read more →

FDA approves Apellis’ Empaveli (pegcetacoplan) as the first C3G and primary IC-MPGN treatment for patients 12 and older

28 July 2025 - Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence. ...

Read more →

PTC Therapeutics announces FDA approval of Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria

28 July 2025 - Broad labelling inclusive of all disease subtypes for individuals 1 month of age and older. ...

Read more →

FDA approves Skytrofa (lonapegsomatropin-tcgd) for the once weekly treatment of adults with growth hormone deficiency

28 July 2025 - On track to initiate basket trial for idiopathic short stature, SHOX deficiency, Turner syndrome, and short ...

Read more →

Highlights from the 21-24 July 2025 CHMP meeting

25 July 2025 - The EMA’s CHMP recommended 13 medicines for approval at its July 2025 meeting. ...

Read more →

Vertex announces marketing authorisation in Canada for Alyftrek, a once daily next generation CFTR modulator for the treatment of cystic fibrosis

22 July 2025 - Approximately 3,800 people in Canada are now eligible for Alyftrek, with up to 60 people potentially ...

Read more →

Sobi announces US FDA approves Doptelet (avatrombopag) for the treatment of thrombocytopenia in paediatric patients one year and older with persistent or chronic immune thrombocytopenia

25 July 2025 - The primary outcome was met in 27.8% of patients, confirming the efficacy in children and adolescents ...

Read more →

Pfizer and BioNTech receive positive CHMP opinion for LP.8.1 adapted COVID-19 vaccine in the European Union

25 July 2025 - Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sub-lineages ...

Read more →

Gilead receives positive CHMP opinions under accelerated review from EMA for twice yearly lenacapavir for HIV prevention

25 July 2025 - Positive opinion also received for EMA’s EU-M4all Procedure, designed to facilitate availability in low- and lower-middle-income countries. ...

Read more →

Roche provides regulatory update on Elevidys gene therapy for Duchenne muscular dystrophy in the EU

25 July 2025 - Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys ...

Read more →

Health Canada grants marketing authorisation for Bayer’s Lynkuet (elinzanetant)

25 July 2025 - Authorisation is supported by data from the Phase 3 OASIS clinical trial program evaluating Lynkuet for the ...

Read more →

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

25 July 2025 - Approval based on GMMG-HD7 Phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD ...

Read more →

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

25 July 2025 - This positive opinion by the EMA’s CHMP is based on results from the explorer8 trial, which ...

Read more →

Mirvetuximab soravtansine approved to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer

24 July 2025 - The approval is supported by a study involving 453 adults with advanced platinum-resistant cancers of the ovary, ...

Read more →